Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Deerfield Management Company, established in 1994, is a prominent investment firm headquartered in New York City. The firm specializes in the healthcare sector and manages over $15 billion in assets as of December 2024. Deerfield's approach integrates investment strategies with philanthropic efforts, particularly through the Deerfield Foundation, which aims to improve children's health worldwide.
Over the years, Deerfield has evolved into a significant player in the healthcare investment landscape, focusing on a diverse portfolio that includes over 200 private and public companies. The firm has made notable strides in advancing healthcare innovation, leveraging its extensive resources and expertise to support companies at various stages of development.
Deerfield's commitment to healthcare is reflected in its operational model, which combines venture capital with hedge fund strategies. This unique structure allows the firm to provide flexible funding solutions tailored to the needs of its portfolio companies.
Deerfield Management invests across a broad spectrum of the healthcare ecosystem, targeting sectors such as therapeutics, medical devices, healthcare services, diagnostics, and digital health. The firm engages in various stages of investment, from Friends & Family and Angel rounds to Series A through Series F, as well as Growth Equity and Pre-IPO funding. This comprehensive approach enables Deerfield to support companies from early-stage startups to mature enterprises.
The firm typically invests through flexible funding models, allowing for tailored financial solutions that meet the specific needs of each company. Deerfield's investment thesis emphasizes advancing healthcare through strategic investments, particularly in therapeutics and innovative healthcare services. The firm seeks to partner with founders who demonstrate a strong vision and commitment to improving healthcare outcomes.
Deerfield Management's portfolio includes over 200 companies, showcasing a diverse range of healthcare innovations. Notable portfolio companies include:
Additionally, Deerfield has made early investments in publicly traded companies such as Nuvalent, Bicara Therapeutics, and Arvinas, all of which have achieved significant market presence.
Jim Flynn: Managing Partner. Jim has been with Deerfield since its inception and has extensive experience in healthcare investments.
Konstantinos Aprilakis, M.D.: Partner. Dr. Aprilakis brings a medical background and expertise in therapeutics to the firm.
Sumner Anderson: Partner. Sumner has a strong track record in healthcare investments and strategic partnerships.
Nicholas Bishop, Ph.D.: Partner. Nicholas specializes in biotechnology and has led numerous successful investments in the sector.
Brian Bizoza, M.D.: Partner. Brian's medical expertise enhances Deerfield's focus on healthcare innovation.
Anne Daub: Partner. Anne has a background in healthcare services and contributes to the firm's investment strategy.
To pitch to Deerfield Management, founders should send an email to karenh1@deerfield.com. A concise pitch deck is essential, highlighting the business model, market opportunity, and team qualifications. Founders should expect a response within a few weeks, and warm introductions are preferred but not mandatory.
Deerfield Management operates the Deerfield Discovery and Development (3DC), an internal R&D engine that advances early-stage therapeutics from discovery through preclinical proof of concept. This program aims to support innovative healthcare solutions and bridge the gap between research and commercialization.
Additionally, Deerfield has established Cure, a healthcare innovation campus that houses various life science and healthcare companies, fostering collaboration and innovation in the sector.
In March 2026, Deerfield Management announced the closing of its Healthcare Innovations Fund III, which has a size of over $600 million. This fund will continue to support innovative healthcare companies globally.
Deerfield has been actively publishing reports on gender gaps in venture-backed healthcare companies, highlighting its commitment to diversity and inclusion in the sector.
The firm also hosts the annual AML Summit, which focuses on advancing research in acute myeloid leukemia, fostering collaboration among researchers and healthcare professionals.
What are Deerfield Management's investment criteria?
Deerfield focuses on healthcare investments across various stages, including early-stage startups and mature companies. The firm looks for innovative solutions in therapeutics, medical devices, and healthcare services.
How can I apply or pitch to Deerfield Management?
Founders can reach out via email at karenh1@deerfield.com to discuss potential investment opportunities. A well-prepared pitch deck that outlines the business model, market opportunity, and team is recommended.
What differentiates Deerfield Management from other investors?
Deerfield's unique philanthropic model sets it apart, as a portion of profits from its Healthcare Innovations Fund III is donated to the Deerfield Foundation, which focuses on improving children's health globally.
What is the geographic scope of Deerfield's investments?
Deerfield invests globally, with a strong focus on North America, targeting companies that are innovating within the healthcare sector.
What is the typical check size for investments?
While specific check sizes are not disclosed, Deerfield's flexible funding models allow for a range of investments from early-stage funding to larger growth equity rounds.
What kind of post-investment involvement does Deerfield have?
Deerfield provides strategic guidance, access to a network of industry experts, and resources for research and development to its portfolio companies, enhancing their growth potential.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.